<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070495</url>
  </required_header>
  <id_info>
    <org_study_id>6356-008</org_study_id>
    <nct_id>NCT04070495</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin</brief_title>
  <official_title>A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of CYP3A4/5 inhibitor or inducer on
      the pharmacokinetics of KW-6356 when CYP3A4/5 inhibitor or inducer is orally administered to
      healthy Japanese men for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Actual">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean ratio of the pharmacokinetic parameter (AUC0-t) of KW-6356 in combination with or without a perpetrator drug</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of KW-6356 in combination with or without a perpetrator drug</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio of the major pharmacokinetic parameters (AUC0-∞) of KW-6356 in combination with or without a perpetrator drug</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (tmax) of KW-6356</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (CL/F) of KW-6356</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Vz/F) of KW-6356</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (t1/2) of KW-6356</measure>
    <time_frame>Starting just before intake of KW-6356 and continued until 168 or 336 hours after intake of KW-6356.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of a perpetrator drug</measure>
    <time_frame>Starting just before intake of a perpetrator drug at Day 8 and continued until 12 or 24 hours after the last dose of a perpetrator drug.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Starting 24 hours before intake of KW-6356 and continued until 14 days after the last dose of a perpetrator drug.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>A single oral dose will be administered at Day 1 and 15</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_label>Rifampicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28</description>
    <arm_group_label>Clarithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21</description>
    <arm_group_label>Rifampicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects having issued written consent to this study at their own discretion

          2. Japanese men aged 20 to 44 years at the time of informed consent

          3. Subjects with BMI ≥18.5 and &lt;25.0 at screening

          4. Subjects with screening results of; resting pulse rate: 40 to 100 bpm, systolic blood
             pressure: 90 to 139 mmHg, diastolic blood pressure: 40 to 89 mmHg

        Exclusion Criteria:

          1. Subjects with any current disease requiring treatment

          2. Subjects having drug allergy or its history

          3. Subjects having psychiatric disease or its history

          4. Positive results for any of the following infection-related items examined at
             screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc)
             antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV)
             antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin
             (PRP) test, or Treponema pallidum (TP) antibody.

          5. Subjects with clinically significant abnormality detected on 12-lead electrocardiogram
             (ECG) recorded prior to the first administration of investigational product.

          6. Subjects categorized as patients listed in the warnings or contraindications section
             of the package insert of the perpetrator drug.

          7. Subjects having used any drug (including over-the-counter [OTC] drugs, topical agents,
             vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks
             prior to the first administration of investigational product.

          8. Subjects having consumed grapefruit (including any food or beverage containing
             grapefruit) or any food or beverage containing St John's wort within 1 week prior to
             the first administration of investigational product.

          9. Subjects having smoked or used smoking cessation agents (including chewing or eating
             of nicotine-containing products and application of nicotine patches) within 4 weeks
             prior to the first administration of investigational product.

         10. Subjects having received inpatient treatment or surgery within 12 weeks prior to the
             first administration of investigational product.

         11. Subjects having participated in a clinical study of a pharmaceutical product or a
             medical device or any equivalent study and used the investigational product or the
             unapproved medical device within 4 months prior to the first administration of
             investigational product.

         12. Subjects having undergone ≥400 mL of blood collection within 12 weeks prior to the
             first administration of investigational product or ≥200 mL of blood collection within
             4 weeks prior to the first administration of investigational product (for blood
             donation or clinical trial, etc.) or pheresis donation (plateletpheresis or
             plasmapheresis donation) within 2 weeks prior to the first administration of
             investigational product.

         13. Subjects having issued no consent to adoption of any appropriate contraceptive method
             during the period from day of admission to 12 weeks after the final administration of
             the perpetrator drug. The appropriate contraceptive method is defined as sexual
             abstinence or use of 2 of the following contraceptive devices: condom, oral
             contraceptives, intrauterine device, and pessary.

         14. Subjects having received KW-6356 before.

         15. Other subjects unsuitable for participating in the study in the opinion of the
             investigator or subinvestigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Co. LTA Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

